Pharmacokinetics of recombinant human insulin-like growth factor I given subcutaneously to healthy volunteers and to patients with growth hormone receptor deficiency.

The pharmacokinetics of recombinant human insulin-like growth factor I (rhIGF-I) were studied in healthy volunteers and in patients with growth hormone receptor deficiency (GHRD; Laron syndrome). Following single subcutaneous injections of rhIGF-I, 40 and 80 micrograms/kg, to healthy volunteers, the peptide was absorbed slowly, with a maximum concentration reached after about 7 hours. Following daily multiple subcutaneous injections of rhIGF-I, 40 micrograms/kg, trough concentrations of IGF-I were increased by 277 +/- 50 micrograms/l (mean +/- SD) from baseline.

Pharmacokinetic profile of recombinant human insulin-like growth factor I given subcutaneously in normal subjects.

The pharmacokinetic profile of recombinant human insulin-like growth factor I (IGF-I) was studied in healthy volunteers. Following a single subcutaneous injection of 40 micrograms/kg or 80 micrograms/kg, mean serum IGF-I concentrations increased by 150 ng/ml and 245 ng/ml, respectively. During repeated daily injections of 40 micrograms/kg, a steady-state IGF-I level of 150 ng/ml above baseline was reached.

Clinical spectrum of the syndrome of growth hormone insensitivity. Advisory Committee on Growth Hormone Insensitivity.

A survey of 46 patients with suspected growth hormone (GH) insensitivity is presented. Clinical details and plasma samples from these patients were analysed centrally. A diagnostic score based on basal levels of GH and insulin-like growth factor I (IGF-I), IGF-I response to GH (0.

Recombinant human growth hormone treatment in short children with chronic renal disease, before transplantation or with functioning renal transplants: an interim report on five European studies.

Growth retardation is common in children with chronic renal disease. Final adult height is often reduced, even in children with a functioning renal transplant. The five European studies considered here aim to investigate the efficacy and safety of recombinant human growth hormone therapy (rhGH) in two groups of short children with chronic renal disease.

An open-labelled study of the safety, acute metabolic activity and pharmacokinetic profile of a short-term course of recombinant human growth hormone in healthy volunteers.

The safety and short-term biological effects of recombinant human GH (Genotropin, KmbiVitrum AB, Stockholm, Sweden), given i.m. (8 IU/d) for 4 consecutive days to 10 healthy male volunteers, have been evaluated.

Effect of domperidone on apomorphine inhibition of the copulatory response and exploratory behaviour in the female rat.

The effects of domperidone, a peripheral dopamine receptor blocker which poorly crosses the blood-brain barrier, on copulatory and exploratory behaviour were studied in apomorphine (oestrogen + progesterone) treated ovariectomized rats. The dose of domperidone (1.0 mg/kg) which clearly prevented the inhibitory action of apomorphine on the lordotic response did not influence the effect of apomorphine in an exploratory test situation.

Involvement of 5-HT2 receptors in the LSD- and L-5-HTP-induced suppression of lordotic behavior in the female rat.

Copulatory behavior in the ovariectomized rat, the lordotic response (L.R.), was induced by estrogen followed by progesterone.

Progesterone enhancement of lysergic acid diethylamide and levo-5-hydroxytryptophan stimulation of the copulatory response in the female rat.

Copulatory behavior in the ovariectomized rat, i.e. the lordosis response (LR) on being mounted by a male, can be induced by administration of either estrogen alone or estrogen followed by progesterone.

Enhancement by progesterone of 5-hydroxytryptophan inhibition of the copulatory response in the female rat.

A study was made of the influence of different hormonal treatments used to induce copulatory behavior in ovariectomized female rats (lordosis behavior), on the effects of an endogenous increase of 5-HT or catecholamines achieved by DL-5-HTP and L-Dopa. The lordosis response (LR) has been shown to be inhibited by increased serotonergic and catecholaminergic neuronal activity. The 5-HT agonist lysergic acid diethylamide (LSD) has been found to inhibit the LR.

Enhancement by progesterone of lysergic acid diethylamide inhibition of the copulatory response in the female rat.

Copulatory behavior in the ovariectomized rat, the lordosis response (L.R.) was induced by either estrogen alone or estrogen followed by progesterone.